ALDX
Aldeyra Therapeutics, Inc.
There isn't enough reported data to score ALDX yet.
ALDX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ALDX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ALDX PE Valuation
ALDX has no meaningful PE right now: it lost money over the past year.
ALDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect ALDX's losses to shrink, with revenue holding steady.
ALDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.31 | +$0.42 |
| Q2 2026 | -$0.38 | +$0.47 |
| Q1 2026 | -$0.45 | +$0.52 |
| Q4 2025 | -$0.56 | +$0.38 |
| Q3 2025 | -$0.73 | +$0.02 |
| Q2 2025 | -$0.85 | -$0.21 |
| Q1 2025 | -$0.97 | -$0.46 |
| Q4 2024 | -$0.94 | -$0.30 |
ALDX is still losing money, but far less than before: $0.31 per share over the past year, against $2.24 at its worst in late 2019.
ALDX Quarterly Revenue
ALDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.1M | +$2.9M |
| Q2 2026 | -$4.6M | +$4M |
| Q1 2026 | -$5.1M | +$7.4M |
| Q4 2025 | -$5.3M | +$6.7M |
| Q3 2025 | -$7M | +$953.5K |
| Q2 2025 | -$8.6M | +$4.7M |
| Q1 2025 | -$12.5M | -$2.5M |
| Q4 2024 | -$12M | -2505% |
ALDX has burned cash in almost every quarter: −$19M over the past year, against −$40M the year before.
ALDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +30.5K shares |
| 1 year | +0.4% | +225K shares |
| 3 years | +2.3% | +1.4M shares |
| 5 years | +4% | +2.3M shares |
| Available history | +123% | +33.2M shares |
ALDX has 60M diluted shares, about the same as a year ago.
ALDX Net Leverage
ALDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ALDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.6 | Oversold |
| Stochastic | 6.7 | Oversold |
ALDX's weekly RSI is 27 (oversold) and its Stochastic is 7 (oversold).
ALDX PE vs Healthcare Sector
ALDX has no meaningful PE right now: it lost money over the past year.
ALDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.81 | 22% below |
| 20 week MA | $1.29 | 51% below |
| 50 week MA | $2.51 | 75% below |
| 100 week MA | $3.58 | 82% below |
| 200 week MA | $4.58 | 86% below |
ALDX is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
ALDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.50 | $7.27 | +12% |
| 2021 | $7.27 | $4.17 | -43% |
| 2022 | $4.17 | $6.60 | +58% |
| 2023 | $6.60 | $3.51 | -47% |
| 2024 | $3.51 | $4.94 | +41% |
| 2025 | $4.94 | $5.31 | +7.5% |
| 2026 YTD | $5.31 | $0.63 | -88% |
ALDX is down 88% so far in 2026, after finishing higher in four of the previous six years.